D.Vijay kumar Dist.Sales Manager Abbott Hyderabad.

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

HIV Counselling and Testing
Unit 6 Diagnosis & Follow-up of HIV Infection
Dr. Kate Templeton SPAIIN –Stirling Overview HIV Infection Tests used in diagnostic labs How to access them Challenges HIV prevention Non –conformity.
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
GENERAL AWARENESS ON HIV/AIDS Presented by: WeHELP In Association with its MEDICAL TEAM.
Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics.
Comparison of the HIV LIA vs WB on HIV-Negative Samples CDC-HIV Diagnostics Meeting “New Diagnostic Technologies” Dec 5-7, 2007 Dr. John Kim National Laboratory.
HIV TESTING TECHNOLOGIES ELISA / WESTERN BLOT.
CDC Recommendations for HIV Testing of Adults and Adolescents Christina Price, MPH Delta Region AIDS Education and Training Center.
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Diagnosis of HIV Infection
Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation J2J Global Media Training on HIV/AIDS July 14, 2010 Vienna, Austria.
Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Attending Physician Ronald Reagan Medical Center Center for World Health and Division.
Enzyme Linked Immunosorbent Assay (ELISA) Rapid Test Western Blot Assay.
Learning Objectives How to detect HIV antibodies/HIV infection?
Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Attending Physician Ronald Reagan Medical Center Center for World Health and Division.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
HIV Testing CDC power point edited by M. Myers
Laboratory Investigation
Dr Don Ajith Karawita MBBS, PgD Ven, MD Venereology National STD/AIDS Control Programme.
HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.
Incorporation of the Aptima® HIV-1 RNA Assay into Serodiagnostic and Rapid Test Confirmation Testing Algorithms to Resolve Discordant Serological Results.
HIV Testing Quality Assurance and Quality Control
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
Inputs to a case-based HIV surveillance system. Objectives  Review HIV case definitions  Understand clinical and immunologic staging  Identify the.
Chapter 30 Lesson 2 Treatment for HIV and AIDS. Detecting HIV Antibodies 2 phases of testing that have and accuracy of 99% Takes anywhere from 2 weeks.
Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.
HIV/AIDS is preventable and treatable, but is incurable.
HIV Diagnosis Jose-Luis Burgos, MD, AAHIVM Prevenmed-UCSD International Heath & Cross Cultural Medicine.
HCV Diagnosis. Features of Hepatitis C Virus Infection Incubation periodAverage 6-7 weeks Range 2-26 weeks Acute illness (jaundice)Mild (
SECTION IV PREVENTION OF HIV AND AIDS. Module 11: HIV AND AIDS TRANSMISSION AND PREVENTION.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
New HIV Test Algorithms and Revised Adult HIV Case Report Form (DCH #1355) HIV Surveillance HIV/STD/VH/TB Epidemiology Section Bureau of Epidemiology Michigan.
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
SCREENING Asst. Prof. Sumattna Glangkarn RN, MSc. (Epidemiology), PhD (Nursing studies)
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
P1 1 Summary of the training modules. P2 2 Introduction You know now what is HIV and what is AIDS. How HIV is acquired, how it causes disease what are.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Prevention of Mother to Child HIV Transmission Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation July 15, 2009 Cape.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Diagnosis of AIDS Dr.T.V.Rao, MD..
Clinical case 19 Lin, I-Yao (Sally). Case 19 Having been confined in the hospital for almost a month due recurrent pneumonia, Mr. XXX, 42 y/o, married,
Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.
Provider initiated testing in Kenya Ruth Nduati Associate Prof Paediatrics University of Nairobi.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and.
OnSite HEV Rapid Test.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
Interventions for Clients with HIV/AIDS and Other Immunodeficiencies.
 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.
BioPlex 2200 HIV Ag-Ab Assay
RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
Overview of HIV Testing Technologies
Provider Initiated HIV Counseling and Testing Unit 2: Introduction and Rational for PIHCT.
 Direct  Indirect  Direct: -Microscopy -Culture -Antigen -Nucleic acid  Indirect: -Specific antibody (Serology)
1 Module 2: HIV Counseling and Testing for PMTCT Ministry of Health/HAPCO, Ethiopia.
MICROBIOLOGY IRS. Gastroenteritis 1) Major cause of infantile death 2) Feacal-oral transmission 3) Gastroenteritis cause dehydration 4) 50 % of all causes.
A REVIEW ON HIV DIAGONOSTIC TEST
CHILDREN and HIV.
In The Name of God.
California Clinical Laboratory Association
Laboratory Diagnosis of Infectious Diseases
مبانی و اصول تشخیص اچ‌آي‌وي
UNAIDS/WHO POLICY ON HIV TESTING June 2004
1985: First HIV-1 ELISA Approved by FDA
Presentation transcript:

D.Vijay kumar Dist.Sales Manager Abbott Hyderabad. HIV TESTING PROTOCOLS D.Vijay kumar Dist.Sales Manager Abbott Hyderabad.

* HIV testing – voluntary Mandatory testing – counterproductive Informed consent prior to testing is essential to deal with issues like- Confidentiality Discrimination Victimization Psychological harm * HIV testing – voluntary Mandatory testing – counterproductive

Purpose of HIV testing

Transfusion safety Epidemiological - Sentinel surveillance Diagnostic purpose Voluntary testing Research

PPTCT Pregnant HIV infected women can- make informed decisions about dealing with pregnancy receive appropriate and timely interventions to decrease MTCT ensure safe delivery secure early access to HIV care and treatment educated in prevention of HIV transmission receive follow-up health care for self and child Pregnant HIV non infected women can be educated and counselled to remain uninfected

Serological Profile of HIV infection

Tests for detecting HIV INFECTION Detection of specific antibodies screening tests: 100% sensitive supplemental/ confirmatory tests- sens. > 99.8% spec. > 98.5% Detection of specific antigens

Accuracy with which a test can confirm the presence of an infection. SELECTION OF TESTS : BASED ON SENSITIVITY ,SPECIFICITY,EFFICIENCY,PPV & NPV Sensitivity – Accuracy with which a test can confirm the presence of an infection. Test with high sensitivity – few false negatives TP Sensitivity = x 100 TP + FN

SPECIFICITY- Accuracy with which the test can confirm the absence of an infection test with high specificity – few false positives used for diagnosing infection in an individual TN Specificity = X 100 TN + FP

Efficiency - ability of a test to correctly identify - all positives as positives all negatives as negatives TP + TN Efficiency = X 100 TP + FN + TN + FP

Predictive values PPV – identifies ACTUALLY infected individuals TP X 100 TP + FP NPV – identifies ACTUAL non infected TN TN + FN

ELISA Most common screening test Indirect solid phase enzyme linked immunosorbent assay/ EIA Used in blood banks/ tertiary labs Fourth generation ELISA decreases window period DISADVANTAGES Many false positives Few false negatives Time consuming Needs infrastructure & tech. expertise

PRINCIPLE OF INDIRECT ELISA Substrate Enzyme conjugated Anti-HIV antibody in specimen Antigen On solid phase

ELISA cont. False positives: auto immune diseases multiple pregnancies hematologic malignancies primary biliary cirrhosis alcoholic hepatitis CRF False negatives window period immunosuppressive therapy malignant disorders late stage disease technical errors

Rapid tests Dot blot assay- immuno concentration method Retroquic -line assay Tridot - dot assay Immunocomb assay – dipstick/comb ELISA based HIV comb coomb AIDS Immunochromatography – lateral flow assays Determine,Unigold,Hemastrip Particle aggluttination – Capillus,Serodia ELISA based - EIA

Comb AIDS NON-REACTIVE INVALID TEST Dot immunoassay for HIV 1&2 using whole blood,serum or plasma. Comb with 8 teeth- Megenta red spot Synthetic& recombinant peptides used Two spots-- Control spot & test spot. NON-REACTIVE REACTIVE For HIV-1 &2 INVALID TEST

TRIDOT HIV 1 – gp 41, gp 120. HIV 2 – gp 36. Highly specific. C 1 2

RETROQUIC HIV

HIV EIA Comb

INTERPRETATION OF RESULTS HIV EIA Comb Rapid Visual EIA Test Detection of Antibodies to HIV-1 (including subgroups O & C) and HIV-2 Sensitivity (100%) Specificity (99.9%) INTERPRETATION OF RESULTS NON-REACTIVE HIV-1 HIV-2 HIV-1&2 REACTIVE INVALID TEST

SUPPLEMENTAL TESTS 1.Rapid tests. 2.Western blot. 3.Immunoblot. 4.Line immunoassay. WB/IB/LIA: highly specific but Expensive Labour intensive Needs expertise Equivocal/indeterminate results.

Western Blot for HIV Delineates the antibody profile of reactive serum Used to grade intensity of ab response Qualitatively Quantitatively Procedure based on principle of ELISA WB Rotator platform WB strips

Western blot for HIV antibody gp 36 Control band p 24 gp 31 gp 41 gp 120 & 160

TESTS DONE IN VCCTC, PPTCT & BLOOD BANK Test – I: HIV Comb / Comb Aids – RS Test – II: Tridot / Retroquic Test – III: EIA Comb FOR SURVEILLANCE: BLOOD BANK: Only Test: Microlisa HIV

STRATEGIES/ALGORITHMS OF HIV TESTING 1.Screening ELISA/Rapid tests – used in strategy I, II, III. 2.Supplemental tests – E/R & Western Blot. Strategy I (for transfusion/transplantation safety) one test kit required AI A1 + A1 - positive negative

Strategy/Algorithm II A (for surveillance) 2 test kits required A1 A1 + A1 - Report negative A2 A1 + A2 + A1+ A2 - Report positive Report negative

Strategy/Algorithm II B (Diagnosis of an individual with AIDS indicator disease symptoms) 3 test kits required A1 A1 + A1 - report negative A2 A1+ A2 + A1+ A2 - report positive A3 A1+ A2 – A3+ A1+ A2 - A3- indeterminate report negative

Strategy/Algorithm III To detect HIV infection in asymptomatic individuals (VCTCs, PPTCTs) 3 test kits required A1 A1+ A1 - Report negative A2 A1+ A2 + A1+ A2 – A3 A1+ A2+ A3+ A1+ A2+ A3- A3 Report positive indeterminate A1+ A2- A3+ A1+ A2- A3- Indeterminate report negative

INDETERMINATE STATUS: Repeat test after 14-28 days INDETERMINATE STATUS: Repeat test after 14-28 days. Results continue to be indeterminate – WB/PCR refer to NRL. EQUIVOCAL WB: Rpt. WB after 2 weeks 4 weeks 12 weeks one year. Correlate with high risk behaviour & clinical parameters.

TESTS TO DETECT ANTIGENS P24 Antigen: Uncomplexed in serum, plasma, CSF, cell culture. Indicates Active infection especially in newborn. Resolves equivocal WB. Window period. CNS disease. Immune collapse. Monitoring response to ART. Method: EIA Disadvantages: Expensive. Limited sensitivity. Failure to detect HIV 2. Failure to detect Ag when complexed with Antibody

Limitations of antigen detection methods Not reliable Expensive Limited sensitivity-69% in patients with AIDS,15% in neonates Detection not possible in patients with high anti p24 antibody Cannot be used as a screening test

PCR Highly specific test-more than 95% Highly sensitive-infants over 1 month Detects proviral DNA . Detects both latent viral infection and active viral transcriptipn. Detects viral load. Detects both HIV1 & HIV2.

PCR AS VIRAL ASSAYS IN INFANTS Counselling for infant feeding & therapeutic intervention. First done at 6 weeks. Not Breast-fed, to say not infected: 2 negative test after 1 month (include 1 at 4 months) Not done as part of PPTCT in India. If symptoms occur at < 18 months: go for viral assays.

Diagnosing HIV infection in an infant born to HIV positive mother Protocol 1 Asymptomatic 18 months-ELISA Non-reactive Reactive Conditionally consider confirm with a retest Non-infected Re-test NR HIV Unifected

PROTOCOL 2 SYMPTOMATIC Early symptoms AIDS Earlier than 12 mon. defined symptoms Viral assay at 6 weeks same as for early Whenever symptoms occur symptoms Retest 1 month later If both are reactive consider reactive ELISA at 12 months Non reactive Reactive Follow protocol 1 conditionally consider HIV +ve Retest at 18 months retest at 18 months Non reactive reactive HIV UNIFECTED HIV INFECTED

HIV TESTING POLICY IN PPTCT PARENT: Informed consent of the patient Pre n post test counselling Routine testing with three rapid tests first: highly sensitive test-NR-reported with exception of WP Indeterminate: 1st test reactive, 2nd/3rd NR repeat test after 14-28 days. WB/PCR: For persistent indeterminate cases. INFANT OF HIV + MOTHER, ASYMPTOMATIC: ELISA at 18 months—NR—Retest—NR—uninfected. Reactive—consider infected, confirm with retest. INFANT OF HIV + MOTHER, SYMPTOMATIC: ELISA at 12 months—NR—retest NR—uninfected. Reactive—retest R at 18 months—infected.